Study identifier:D5244C00001
ClinicalTrials.gov identifier:NCT05583227
EudraCT identifier:2022-001294-31
CTIS identifier:2023-504277-20-00
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING).
Eosinophilic Esophagitis
Phase 3
No
-
All
360
Interventional
12 Years - 80 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
Amgen
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Tezepelumab Low Dose Tezepelumab subcutaneous injections, in accessorised pre-filled syringes | Biological/Vaccine: Tezepelumab Tezepelumab subcutaneous injection Other Name: Tezepelumab |
Experimental: Tezepelumab High Dose Tezepelumab subcutaneous injections, in accessorised pre-filled syringes | Biological/Vaccine: Tezepelumab Tezepelumab subcutaneous injection Other Name: Tezepelumab |
Placebo Comparator: Placebo Placebo subcutaneous injections, in accessorised pre-filled syringes | Other: Placebo Placebo subcutaneous injection Other Name: Placebo |